Aardvark Therapeutics, Common Stock Performance
| AARD Stock | 13.65 0.61 4.28% |
Aardvark Therapeutics, has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 3.12, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aardvark Therapeutics, will likely underperform. Aardvark Therapeutics, right now shows a risk of 6.21%. Please confirm Aardvark Therapeutics, semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to decide if Aardvark Therapeutics, will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Aardvark Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Aardvark Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
Actual Historical Performance (%)
One Day Return (4.28) | Five Day Return (1.16) | Year To Date Return (4.61) | Ten Year Return (4.61) | All Time Return (4.61) |
1 | Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome | 10/08/2025 |
2 | Acquisition by Bryan Jones of 1250 shares of Aardvark Therapeutics, at 4.24 subject to Rule 16b-3 | 10/15/2025 |
3 | Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 | 11/04/2025 |
4 | Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 - The Manila Times | 11/12/2025 |
5 | Aardvark Therapeutics Issues Quarterly Earnings Results, Beats Estimates By 0.07 EPS | 11/14/2025 |
6 | Individual investors among Aardvark Therapeutics, Inc.s largest shareholders, saw gain in holdings value after stock jumped 23 percent last week | 12/04/2025 |
7 | Acquisition by Lee Tien-li of 7000 shares of Aardvark Therapeutics, at 14.485 subject to Rule 16b-3 | 12/11/2025 |
8 | Aardvarks Hunger Suppressing Drug Candidate Could Potentially Address Massive 10 Billion Market Analyst | 12/12/2025 |
9 | Insider Buying Aardvark Therapeutics CEO, Secretary Director Bought US101k Of Shares | 12/15/2025 |
| Begin Period Cash Flow | 9.7 M | |
| Total Cashflows From Investing Activities | -12 M |
Aardvark Therapeutics, Relative Risk vs. Return Landscape
If you would invest 1,368 in Aardvark Therapeutics, Common on September 29, 2025 and sell it today you would lose (3.00) from holding Aardvark Therapeutics, Common or give up 0.22% of portfolio value over 90 days. Aardvark Therapeutics, Common is currently generating 0.1766% in daily expected returns and assumes 6.212% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Aardvark, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aardvark Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aardvark Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aardvark Therapeutics, Common, and traders can use it to determine the average amount a Aardvark Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0284
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AARD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Aardvark Therapeutics, is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aardvark Therapeutics, by adding it to a well-diversified portfolio.
Aardvark Therapeutics, Fundamentals Growth
Aardvark Stock prices reflect investors' perceptions of the future prospects and financial health of Aardvark Therapeutics,, and Aardvark Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aardvark Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 171.4 M | ||||
| Shares Outstanding | 21.77 M | ||||
| Price To Book | 2.43 X | ||||
| EBITDA | (22.65 M) | ||||
| Net Income | (20.59 M) | ||||
| Total Debt | 779 K | ||||
| Book Value Per Share | 5.63 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Earnings Per Share | (2.53) X | ||||
| Market Capitalization | 297.21 M | ||||
| Total Asset | 77.51 M | ||||
| Retained Earnings | (58.33 M) | ||||
| Working Capital | 69.21 M | ||||
About Aardvark Therapeutics, Performance
By analyzing Aardvark Therapeutics,'s fundamental ratios, stakeholders can gain valuable insights into Aardvark Therapeutics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aardvark Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aardvark Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | 0.38 | 0.40 |
Things to note about Aardvark Therapeutics, performance evaluation
Checking the ongoing alerts about Aardvark Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aardvark Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aardvark Therapeutics, had very high historical volatility over the last 90 days | |
| Aardvark Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (20.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aardvark Therapeutics, generates negative cash flow from operations | |
| Aardvark Therapeutics, has a poor financial position based on the latest SEC disclosures | |
| About 15.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Insider Buying Aardvark Therapeutics CEO, Secretary Director Bought US101k Of Shares |
- Analyzing Aardvark Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aardvark Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Aardvark Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aardvark Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aardvark Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aardvark Therapeutics,'s stock. These opinions can provide insight into Aardvark Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aardvark Stock analysis
When running Aardvark Therapeutics,'s price analysis, check to measure Aardvark Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aardvark Therapeutics, is operating at the current time. Most of Aardvark Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Aardvark Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aardvark Therapeutics,'s price. Additionally, you may evaluate how the addition of Aardvark Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |